Trial Profile
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms D-STOP Trial
- 01 Jan 2018 Results published in the Cancer Science
- 06 Dec 2016 Status changed from recruiting to completed.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology